To evaluate the binding characteristics of [3H]Ro15-4513 with the central benzodiazepine (BZ) receptor, inhibition experiments of [3H]Ro15-1788 and [3H]Ro15-4513 were performed both in vitro and in vivo, using two BZ ligands, flunitrazepam (FNP), and ethyl-β-carboline-3-carboxylate (β-CCE). FNP inhibited the binding of [3H]Ro15-1788 and [3H]Ro15-4513 in a dose-dependent manner in the mouse cerebral cortex, hippocampus, and cerebellum, both in vitro and in vivo. β-CCE also inhibited the binding of [3H]Ro15-1788 and [3H]Ro15-4513 in all the aforementioned brain regions in vitro. However, in vivo, β-CCE inhibited the binding of [3H]Ro15-4513 in the cerebral cortex and cerebellum, but not in the hippocampus, even at an injected dose of up to 1mg/kg. In contrast, more than 50% of the in vivo binding of [3H]Ro15-1788 was inhibited by 1 mg/kg of β-CCE in all regions. The time-activity curve of [3H]Ro15-4513 in the hippocampus also showed no alteration of the peak uptake between the control group and 0.3 mg/kg of β-CCE coinjected group. These results indicated that the binding characteristics of [3H]Ro15-4513 with the BZ receptor differed markedly between the in vitro and in vivo condition, and the selectivity of [3H]Ro15-4513 binding to α5 subtype of BZ receptor in the mouse brain seemed to be remarkable under the in vivo condition.
- GABA/BZ receptor
- In vivo
- α5 subtype
ASJC Scopus subject areas
- Cellular and Molecular Neuroscience